Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety and efficacy study of vamorolone in boys with Duchenne muscular dystrophy previously treated with vamorolone
MOH_2024-11-27_013704Phase 4Recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Sep 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zuranolone in Duchenne muscular dystrophy (DMD), sponsored by Santhera Pharmaceuticals. Started Sep 2024; status: recruiting.
02
Drugs
zuranolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2024-11-27_013704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-27_013704.